NTNU Therapeutic Targeting
- NTNU Analysis, Design and Control of Microbial Systems
- NTNU Aquaculture Biotechnology
- NTNU Bioreactor Design and Operation
- NTNU Biopolymer Engineering
- NTNU Genome Editing
- NTNU Human Physiome
- NTNU Morphogenetic Engineering
- NTNU Phenomics Technology
- NTNU Tissue Engineering
- NTNU Synthetic Biology Engineering
- NTNU Therapeutic Targeting
- NTNU Responsible Research and Innovation
Finished project
(R) NTNU Therapeutic Targeting Blurb
NTNU Therapeutic Targeting
We have a proven track record in tailoring biopolymers into new biomaterials for numerous application areas within medicine and industry.
Research activity
The treatment of every illness through the administration of one or more drugs is an act of balance between the imposed therapeutic effect and the potential negative side effects and the fact that beneficial effects are often transient since the cells are able to compensate, by bypassing or activating alternative pathways. Better therapeutic targeting is therefore key to reduce negative effects and enhance efficacy, and thus a prerequisite for precision medicine whether it involves the application of existing drugs, or the development of new drugs or new combinations. It is an endeavour that demands knowledge about human physiology and pathophysiology, capacity for high-dimensional phenotyping, insight into localized drug effects, and ability to perturb – specifically – one or more molecular processes.
This R&D stream focuses areas like cancer research, cardiac research, infections, inflammation and host-pathogen interactions and addresses amongst others drug target identification, discovery and characterisation of biological response modifiers including small molecules and peptides, characterisation of drug-target interaction, model-based drug response prediction and preclinical drug response screening. The R&D stream is closely linked to NTNU Phenomics Technology and NTNU Human Physiome. Research groups working in the area of Therapeutic Targeting are located at numerous NTNU Departments and several SINTEF areas shown below, and at the NTNU hosted Centre of Excellence ‘Centre of Molecular Inflammation Research (CEMIR)’ and at the K. G. Jebsen ‘Center for Myeloma Research’ and K.G. Jebsen ‘Centre for Exercise in Medicine’. The NTNU Strategic Research Area ‘NTNU Health’ supports research within Diagnostics and therapy as one of three main focus areas. This R&D stream research is based on close collaboration with St. Olavs Hospital and other hospitals under the Central Norway Regional Health Authority.